Aristotle University of Thessaloniki at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Aristotle University of Thessaloniki brings 5 presentations to ESGCT 2026 in Hamburg. Its work at the meeting centres on beta-thalassemia and other haemoglobin disorders, using adenoviral and lentiviral platforms to reactivate fetal haemoglobin and select corrected cells. It also models rAAV production and purification in fixed bed bioreactors.
| Organization | ESGCT 2026 Attendance |
|---|---|
Aristotle University of Thessaloniki Thessaloniki, Greece | |
Greece's largest university, with research on gene therapy for haemoglobin disorders. | Talk Wed Oct 28 10:15am–10:30am In vivo HbF reactivation and selective erythroid enrichment using a novel adenoviral platform Vectors and delivery (AAV, lentiviral, LNP)Rare and inherited disease Poster Wed Oct 28 1:30pm–3:30pm Adenoviral vector–mediated in vivo epigenome editing as a therapeutic approach for beta-hemoglobinopathies Poster Wed Oct 28 1:30pm–3:30pm Hybrid modeling of upstream unit operations for rAAV manufacturing in fixed bed bioreactors Poster Thu Oct 29 2:00pm–4:00pm A Mechanistic Model for Predicting AAV9 Recovery During Ion-Exchange Purification Poster Thu Oct 29 2:00pm–4:00pm A dual-function lentiviral gene therapy platform for beta-thalassemia combining fetal hemoglobin induction and in vivo selection of gene-modified cells |
Instantly find 20 buyers from Aristotle University of Thessaloniki
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction